EpiVacCorona COVID-19 vaccine
GPTKB entity
Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:administeredBy |
intramuscular injection
|
| gptkbp:alternativeName |
gptkb:ЭпиВакКорона
gptkb:EpiVacCorona |
| gptkbp:announced |
2020-07-24
|
| gptkbp:antigen |
synthetic peptide
|
| gptkbp:approvalYear |
2020-10-14
|
| gptkbp:approvedBy |
gptkb:Russia
|
| gptkbp:clinicalTrialPhase |
Phase III (as of 2021)
|
| gptkbp:contains |
three synthetic peptides from SARS-CoV-2 spike protein
|
| gptkbp:containsAdjuvant |
aluminum hydroxide
|
| gptkbp:countryOfOrigin |
gptkb:Russia
|
| gptkbp:developedBy |
gptkb:Vector_Institute
|
| gptkbp:doseInterval |
21 days
|
| gptkbp:firstBatchReleased |
2020-10-14
|
| https://www.w3.org/2000/01/rdf-schema#label |
EpiVacCorona COVID-19 vaccine
|
| gptkbp:marketedIn |
gptkb:Belarus
gptkb:Russia gptkb:Turkmenistan gptkb:Venezuela |
| gptkbp:numberOfDoses |
2
|
| gptkbp:regulates |
gptkb:Russian_Ministry_of_Health
|
| gptkbp:storage |
2–8°C
|
| gptkbp:target |
gptkb:COVID-19
|
| gptkbp:type |
peptide vaccine
|
| gptkbp:WHOStatus |
not approved by WHO
|
| gptkbp:bfsParent |
gptkb:VECTOR_Institute_(Russia)
|
| gptkbp:bfsLayer |
6
|